The assets do not include NewYork-Presbyterian’s hospital-based labs. The deal is expected to be completed in the second quarter of 2023, pending regulatory approval. Terms were not disclosed.
“NewYork-Presbyterian and Quest share a belief that exceptional patient care should be accessible to all,” said NewYork-Presbyterian President and CEO Steven Corwin, MD, said in a Feb. 14 Quest news release. “We determined that working with Quest would be the best path — allowing our patients wider access to advanced, quality laboratory services.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
